A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2

Marco P Licciardello; Paul Workman

doi:10.1016/j.tips.2021.02.002

A New Chemical Probe Challenges the Broad Cancer Essentiality of CK2

Trends Pharmacol Sci. 2021 May;42(5):313-315. doi: 10.1016/j.tips.2021.02.002. Epub 2021 Mar 23.

Authors

Marco P Licciardello¹, Paul Workman²

Affiliations

¹ Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK.
² Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK. Electronic address: paul.workman@icr.ac.uk.

PMID: 33771354
DOI: 10.1016/j.tips.2021.02.002

Abstract

Casein kinase 2 (CK2) is highly expressed in cancer and has been considered a potential therapeutic target. Wells and colleagues developed and characterized the new CK2 inhibitor SGC-CK2-1. Unexpectedly, this potent and highly selective chemical probe does not show broad antiproliferative activity in cancer cells.

Keywords: COVID-19; cancer; drug target; neurodegenerative diseases; protein kinase; selective CK2 inhibitor.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Casein Kinase II*
Humans
Neoplasms* / drug therapy
Protein Kinase Inhibitors

Substances

Protein Kinase Inhibitors
Casein Kinase II